Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN versus VELOSEF 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN versus VELOSEF 500.
CEFOTETAN vs VELOSEF '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Cephradine inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis and death. It is a first-generation cephalosporin with bactericidal activity.
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
500 mg orally every 6 hours for 10 days.
None Documented
None Documented
3-4.5 hours (6-8 hours in renal impairment).
Clinical Note
moderateCefotetan + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotetan."
Clinical Note
moderateCefotetan + Ethanol
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Ethanol."
Clinical Note
moderateCefotetan + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotetan."
Clinical Note
moderateCefotetan + Carbocisteine
Terminal elimination half-life: 1.2 hours in adults with normal renal function; prolonged to 8-15 hours in severe renal impairment (CrCl <10 mL/min); clinical context: dosing interval adjustment required for renal impairment
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
Renal excretion of unchanged drug: >90% (glomerular filtration and tubular secretion); biliary/fecal: <1%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Carbocisteine."